Pfizer Oncology 2016 Analyst Call - Ibrance, Avelumab Portfolio

Pfizer's oncology analyst call from June 2016 discussing the company's strategy to establish leadership in cancer treatment through its pipeline and in-line products, including Ibrance and avelumab immunotherapy candidates. The presentation outlines Pfizer's vision to accelerate breakthrough medicines to patients while ensuring accessibility and meaningful clinical impact.